Exelixis Adds Insilico Deal In Search Of Growth Beyond Cabometyx
Company Rides Out Challenge From Activist Investor
After feeling the heat from activist investor Farallon Capital Management earlier this year, CEO Michael Morrissey has defended its spending on in-house R&D and in-licensing as it announced a new oncology deal.
You may also be interested in...
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.
The mid-sized company is under siege from hedge fund Farallon and faces a fight over its R&D strategy to follow aging blockbuster Cabometyx.
The GSK-led joint venture has taken the lead in long-acting HIV treatment and prevention but has put back timelines on a key self-administered candidate.